Caitlin Kontulis
Directeur Financier/CFO chez PHIO PHARMACEUTICALS CORP.
Fortune : 7 514 $ au 30/04/2024
Profil
Caitlin Kontulis is currently working as the Secretary, VP-Finance & Administration at Phio Pharmaceuticals Corp.
Previously, she worked as the Interim Chief Accounting Officer at Galena Biopharma, Inc. She completed her graduate degree from Northeastern University in 2008 and her undergraduate degree from Bryant University in 2007.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 01/03/2024 | 10 643 ( 0,23% ) | 7 514 $ | 30/04/2024 |
Postes actifs de Caitlin Kontulis
| Sociétés | Poste | Début |
|---|---|---|
| PHIO PHARMACEUTICALS CORP. | Directeur Financier/CFO | - |
Anciens postes connus de Caitlin Kontulis
| Sociétés | Poste | Fin |
|---|---|---|
Galena Biopharma, Inc.
 Galena Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Galena Biopharma, Inc. is a biopharmaceutical company, which develops and commercializes hematology and oncology therapeutics that address unmet medical needs. The company focuses on identifying and advancing therapeutic opportunities to improve cancer care from direct treatment of the disease to the reduction of its debilitating side effects. Its products include Abstral sublingual tablets and Zuplenz oral soluble film. The company was founded by Craig Mello on April 3, 2006 and is headquartered in San Ramon, CA. | Comptroller/Controller/Auditor | - |
Formation de Caitlin Kontulis
| Bryant University | Undergraduate Degree |
| Northeastern University | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| PHIO PHARMACEUTICALS CORP. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Galena Biopharma, Inc.
Galena Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Galena Biopharma, Inc. is a biopharmaceutical company, which develops and commercializes hematology and oncology therapeutics that address unmet medical needs. The company focuses on identifying and advancing therapeutic opportunities to improve cancer care from direct treatment of the disease to the reduction of its debilitating side effects. Its products include Abstral sublingual tablets and Zuplenz oral soluble film. The company was founded by Craig Mello on April 3, 2006 and is headquartered in San Ramon, CA. | Health Technology |
